Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib

Combining a fitness tracker technology with real-time patient-reported outcome monitoring associated with interventions through a health care app is a novel strategy to evaluate metastatic breast cancer patients using Palbociclib and endocrine treatment.

Trial Details

NCT ID
NCT05277935
Phase
NA
Sponsor
Beneficência Portuguesa de São Paulo
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Use of the WeCancer app combined with the smartwatch.
Locations (sample)
  • Rio de Janeiro, Brazil|-22.90642,-43.18223
  • São Paulo, Brazil|-23.5475,-46.63611
  • São Paulo, Brazil|-23.5475,-46.63611
  • São Paulo, Brazil|-23.5475,-46.63611

Key Eligibility Criteria

  • Female patients ≥ 18 years of age diagnosed with hormone receptor-positive/ human epidermal growth factor receptor 2- negative metastatic breast ca…
  • The patient must be on treatment for at least three (3) months with Palbociclib and endocrine therapy.
  • Evidence of a signed and dated informed consent document, physically or digitally, indicating that the research participant was informed about all …
  • The patient agrees not to participate in another study with drug intervention while on treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →